Leveraging Lifestyle Medicine for Better Outcomes in Connective Tissue Diseases

Abstract

Background/Objective: Connective tissue diseases (CTDs) are a group of over 200 disorders that significantly impact quality of life due to chronic inflammation and systemic complications. While pharmacological interventions remain the cornerstone of treatment, lifestyle medicine offers a complementary approach to managing these conditions. This article explores the application of lifestyle interventions in CTDs to improve clinical outcomes and reduce disease burden. Methods: A review of current evidence on lifestyle factors, including nutrition, physical activity, sleep, stress management, avoidance of harmful substances, and social connections, was conducted. This review integrates findings from epidemiological studies, clinical trials, and expert recommendations to provide actionable insights for managing CTDs. Results: Key findings highlight the significant role of diet in influencing inflammatory activity and supporting overall health. Specifically, ultra-processed foods and other lifestyle factors could impact the risk of systemic lupus erythematosus (SLE). In contrast, the Mediterranean diet is particularly beneficial for rheumatoid arthritis (RA), offering anti-inflammatory properties and potential improvements in symptoms. Additionally, regular physical activity plays a vital role in preserving joint and muscle function across these conditions. Restorative sleep and effective stress management are critical in mitigating disease activity, as poor sleep and high stress are associated with worsened outcomes. Smoking and alcohol consumption were identified as modifiable risk factors that exacerbate disease progression, emphasizing the importance of lifestyle interventions for improved disease management and overall quality of life. Conclusion: Incorporating lifestyle medicine into the management of CTDs offers a patient-centered approach that complements pharmacologic treatments. By addressing modifiable risk factors, healthcare providers can empower patients to improve quality of life, reduce reliance on medications, and potentially slow disease progression. Further research is needed to establish long-term outcomes and refine intervention strategies.

“Lifestyle medicine offers an effective, patient-centered approach to managing CTDs.”

Introduction

Connective tissue diseases (CTDs) encompass a group of systemic autoimmune disorders that share overlapping features, including inflammation of connective tissues and blood vessels, immune system dysregulation, and a tendency to effect multiple organ systems. These conditions, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjögren’s syndrome, significantly impact quality of life and often require lifelong management. While traditional treatments focus on medication, integrating lifestyle medicine offers a holistic approach to improving outcomes and reducing the burden of disease.

Lifestyle medicine is an evidence-based approach that emphasizes the prevention and management of chronic diseases through the adoption of healthy behaviors. It addresses modifiable factors such as nutrition, physical activity, sleep, stress, and social connections to influence the course of diseases. This comprehensive approach is particularly valuable for CTDs, as these disorders often have multifactorial etiologies and complex systemic manifestations. By targeting the root causes of inflammation and supporting overall well-being, lifestyle interventions have the potential to complement pharmacologic therapies and improve patient outcomes. Furthermore, patients affected by CTDs often have worse outcomes with common conditions like heart disease. In addition, learning and implementing lifestyle measures can empower patients to take an active role in their health, ultimately leading to enhanced quality of life and potentially reduced disease burden.

Understanding Connective Tissue Diseases

CTDs primarily affect the tissues that provide structural and functional integrity throughout the body. A variety of connective tissue is involved, beyond just collagen. ¹ While the causes of CTDs can be genetic, environmental, or idiopathic, research increasingly highlights the role of modifiable lifestyle factors in disease development and progression especially as it can help secondary outcomes. ²

Common CTDs Include

• • Rheumatoid Arthritis: Although not classified as a classic connective tissue disease, this systemic autoimmune condition primarily targets the synovial lining of joints, leading to inflammation, pain, stiffness and joint destruction. Systemic symptoms like fatigue, malaise and depression may accompany disease activity. It affects approximately 1%–2% of the global population, with women being disproportionately affected. ³

• • Systemic Lupus Erythematosus (SLE): A chronic autoimmune disease characterized by multisystem involvement, commonly affecting the skin, joints, kidneys, and nervous system. It primarily affects women of childbearing age, though men and different age groups can be affected as well. ⁴

• • Sjögren’s syndrome: An autoimmune disorder characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to hallmark symptoms of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). The disease can extend beyond exocrine glands, potentially involving the lungs, liver, kidneys, and other organ systems. Sjögren’s syndrome can present as a primary condition or secondary to other autoimmune diseases, with an estimated prevalence ranging from 0.1% to 3% in the general population. ⁵

• • Scleroderma: A group of autoimmune diseases characterized by progressive skin thickening and fibrosis, often accompanied by systemic involvement. The most common presenting feature is cutaneous sclerosis, typically manifesting as hardening and tightening of the skin, especially in the fingers (sclerodactyly), which can lead to swelling and functional impairment. Raynaud’s phenomenon is frequently associated, and visceral organ involvement—including pulmonary fibrosis, pulmonary arterial hypertension, and cardiac dysfunction—is a hallmark of advanced disease. ⁶

• • Polymyositis/Dermatomyositis: These idiopathic Inflammatory Myopathies (IIMs) are rare systemic autoimmune diseases characterized by chronic muscle inflammation, proximal weakness, and systemic features. Dermatomyositis, in particular, is additionally marked by a distinctive rash. There can be inflammation, muscle atrophy or fatty replacement of healthy muscle tissue which can result in weakness and significant disability. Other organ systems, such as lungs, skin, and joints, may also be affected, leading to a wide range of clinical features. ⁷

• • Mixed Connective Tissue Disease (MCTD): A systemic autoimmune condition characterized by overlapping features of SLE, scleroderma, sjögren syndrome and/or polymyositis, strongly associated with high titers of anti-U1 RNP antibodies. ⁸

How can the 6 Pillars of Lifestyle Medicine be Utilized in CTD Management?

Lifestyle medicine emphasizes evidence-based interventions to address the root causes of chronic diseases. The 6 pillars—nutrition, physical activity, sleep, stress management, avoidance of harmful substances, and social connections—provide a framework for CTD care.

Nutrition

A whole-food, plant-predominant diet rich in antioxidants, fiber, and omega-3 fatty acids has demonstrated significant anti-inflammatory effects. For example:

• • Systemic Lupus Erythematosus (SLE): An observational cohort study of 204,175 women found that a higher intake of ultra-processed foods was associated with a 56% increased risk of SLE with a doubled risk for those with the anti-dsDNA antibody. Specifically, sugar-sweetened or artificially sweetened beverage intake was associated with increased SLE risk. ⁹ Adherence to a higher Healthy Lifestyle Index Score (HLIS), which includes 5 factors—alcohol consumption, body mass index, smoking, diet and regular exercise—is associated with a significantly lower risk of developing systemic lupus erythematosus (SLE) overall (HR 0.42, 95% CI 0.25-0.70) and anti-dsDNA–positive SLE (HR 0.35, 95% CI 0.17-0.75). Specifically, women with at least 4 healthy lifestyle factors had the lowest risk. ¹⁰

• • A 2020 study in Frontiers has shown that dietary supplementation with specific macronutrients and micronutrients demonstrates immunomodulatory effects, aiding in the maintenance of immune homeostasis and improving both physical and mental well-being in patients with systemic lupus erythematosus (SLE). These findings lend strong support for an anti-inflammatory diet as a beneficial approach for managing lupus. A diet rich in fiber, polyunsaturated fatty acids (PUFAs, including omega-3 and omega-6), essential vitamins (A, B, C, D, and E), minerals (calcium, zinc, selenium, iron, and copper), and polyphenol-containing foods has been associated with reduced inflammation and enhanced overall health in SLE. Additionally, a low-calorie and moderate-protein intake may further help in controlling disease activity. This evidence reinforces the importance of adopting a well-balanced, nutrient-dense, anti-inflammatory dietary pattern in lupus management. ¹¹

• • Rheumatoid Arthritis (RA): The Mediterranean diet, emphasizing fruits, vegetables, whole grains, and healthy fats, has been linked to reduced disease activity (measured by DAS28 scores) and improved gut microbiota composition. Specifically, patients with RA who had a high adherence to the Mediterranean diet demonstrated a different microbiota makeup including decreased abundance of Lactobacillaceae and Prevotella copri (linked to RA onset and inflammation) along with an increased abundance of Bacteroides fragilis, known for inducing regulatory T cells and suppressing autoimmunity. This research suggests that the Mediterranean diet’s inclusion of fiber, antioxidants, and polyphenols could modulate gut microbiota by reducing intestinal permeability and systemic inflammation. ¹²

Physical Activity

Regular exercise reduces inflammation and enhances physical and mental health. ¹³ According to the Physical Activity Guidelines for Americans, published by the U.S. Department of Health and Human Services, they suggest:

• • 150-300 minutes of moderate-intensity aerobic activity weekly.

• • Strength training to preserve muscle mass and joint function.

• • In inflammatory myositis, exercise regimens have shown anti-inflammatory effects without increasing markers like Creatine Phosphokinase (CPK) levels, countering previous fears about exacerbating inflammation. ¹⁴ Still markers like cpk, aldolase, inflammatory assessments can be done to characterize disease activity. The literature thus far has endorsed various forms of exercise, whether isometric exercises, resistance exercises or aerobic exercises, as safely improving overall disease activity.^15,16

Restorative Sleep

Sleep disturbances are a frequent and significant concern among individuals with rheumatic diseases, contributing to heightened pain sensitivity and fatigue severity. ¹⁷ Research highlights an increased prevalence of primary sleep disorders, such as obstructive sleep apnea (OSA), particularly in rheumatoid arthritis (RA) and other autoimmune conditions. ¹⁸ OSA not only poses risks for cardiovascular health but also correlates with elevated inflammatory markers like IL-6, TNF-α, and CRP, further exacerbating systemic inflammation in these patients. ¹⁹

Patients with autoimmune diseases commonly report unrefreshing sleep, difficulty falling asleep, frequent awakenings, and shortened sleep duration. ²⁰ These disruptions often result from factors like pain, discomfort, and circadian rhythm alterations. In Sjögren’s syndrome, for example, dryness of the eyes and mouth, along with pain, significantly impacts sleep quality, and this can worsen fatigue, pain, and mood disorders.

Given the role of sleep in modulating inflammation and overall health, addressing sleep disturbances through targeted interventions—including sleep apnea screening, managing nocturnal discomfort, and promoting good sleep hygiene—is critical. Referral to a specialized sleep clinic, when necessary, can ensure comprehensive care and better disease management outcomes for these patients. For instance:

• • Sjögren’s syndrome: Over 74% of patients experience poor sleep, leading to fatigue and depression. ²⁰ Many patients report various sleep disturbances, and, in a focus study group, participants complained of unrefreshing sleep, frequent night awakenings, difficulty with sleep onset, short sleep duration, and altered circadian rhythm. ²¹

Discomfort from oral and ocular dryness and leg pain were common contributors to sleep issues, and these sleep disturbances often had a “domino effect,” exacerbating other PSS symptoms like fatigue, pain, and mood disorders. ²¹

Obstructive Sleep Apnea (OSA)

Studies indicate a higher prevalence of primary sleep disorders, such as obstructive sleep apnea (OSA), in certain rheumatic conditions, particularly rheumatoid arthritis (RA). ¹⁸ OSA is a major public health issue, associated with elevated cardiovascular morbidity and mortality. ¹⁹ Patients with OSA frequently exhibit increased levels of acute-phase reactants and pro-inflammatory cytokines.²⁸ In rheumatic disease populations, the coexistence of OSA may exacerbate pain and fatigue symptoms, elevate the risk of cardiovascular complications, and potentially influence circulating inflammatory markers. ¹⁸ Screening for sleep apnea thus should be emphasized in this population if sleep difficulty is present. ²²

Stress Management

Chronic stress triggers inflammatory pathways, worsening CTD symptoms. For example, stress can activate the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system, leading to increased production of pro-inflammatory cytokines like IL-6 and TNF-α.^23,24 Additionally, oxidative stress and neuroendocrine dysregulation are mechanisms through which stress exacerbates inflammation. ²⁵ Techniques such as mindfulness, meditation, and cognitive-behavioral therapy (CBT) have shown efficacy in reducing stress-induced inflammation by modulating these pathways. ²⁶

• • SLE: A 2004 study investigated the impact of stress on symptom severity in patients with systemic lupus erythematosus, focusing on both daily stress and high-intensity stressful life events. Over 6 months, 46 individuals with systemic lupus erythematosus and 12 with chronic discoid lupus recorded their daily stress levels and symptoms. Researchers assessed disease activity using C3 and C4 complement levels, anti-DNA antibodies, the Systemic Lupus Activity Measures (SLAM), and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR). The findings revealed that high-intensity stressful life events did not significantly worsen symptoms. However, daily stress was strongly associated with symptom exacerbation, affecting 74.1% of patients. Patients who experienced prolonged symptom worsening also exhibited increased disease activity, marked by lower C3 and C4 levels and higher anti-DNA antibodies. The study underscores the critical role of daily stress in exacerbating symptoms and highlights the need for effective stress management strategies in lupus care. ²³

• • RA: A scoping review explored how psychological stress is defined and experienced by patients with rheumatoid arthritis (RA), whether these patients experience more stress compared to others, and the risk factors contributing to stress. They found that patients with RA experienced multiple forms of stress, including role stress, social stress (particularly interpersonal stressors), and work-related stress. Patients with RA experienced more work-related and social stress compared to healthy individuals.^27,28

At disease onset, RA patients reported higher stress levels than individuals with osteoarthritis. However, patients with chronic pain syndromes exhibited higher levels of psychological stress compared to those with RA. The implications suggested that stress was not limited to depression or anxiety but included broader psychological and social dimensions.

These findings highlight the importance of a biopsychosocial approach in RA management, addressing both clinical and psychosocial needs. Interventions such as social support and stress management strategies tailored to individual needs could therefore mitigate stress and improve patient outcomes. ²⁴

Avoidance of Harmful Substances

Avoidance of harmful substances is a critical component of lifestyle medicine in managing connective tissue diseases. Certain behaviors and exposures can exacerbate inflammation, worsen disease activity, and undermine the effectiveness of treatment strategies. Harmful substances such as tobacco and alcohol are particularly detrimental due to their direct and indirect effects on systemic inflammation, immune regulation, and overall health.

• • Smoking: Smoking exacerbates joint damage, reduces medication efficacy, and accelerates vascular complications in RA. ²⁹ Studies indicate that smoking increases the risk of developing anti-citrullinated protein antibodies (ACPAs), which are strongly associated with the pathogenesis of RA. ²⁹ Smoking cessation is crucial for reducing disease activity and improving treatment outcomes. ²⁹

• • Alcohol: A study from 2012 investigated environmental exposures in Hungarian IIM patients and their associations with specific autoantibodies. Data from 119 patients (74% female) were collected. Most patients had polymyositis (57%), followed by dermatomyositis (26%) and myositis-connective tissue disease overlap (17%). Notably, smoking and frequent alcohol consumption were significantly more common in anti-Jo-1-positive patients, suggesting these environmental factors may contribute to anti-Jo-1 autoantibody development. In this group, Anti-SSA/SSB-positive patients were younger at diagnosis, predominantly female, and more likely to report stressful life events in the year preceding diagnosis. No significant associations were found between infections, medications, vaccinations, or chemical exposures and autoantibody status. These findings underscore the potential role of environmental factors in IIM pathophysiology and highlight the need for further research into the interplay between environment and genetics. ³⁰

Social Connections

Strong social networks improve health outcomes and resilience in chronic disease management. Encouraging patients to engage with support groups and maintain meaningful relationships fosters emotional well-being.

A 2024 qualitative study examined the psychosocial factors that impact effective management of rheumatoid arthritis (RA), focusing on patient experiences to identify contributors to persistently active disease. Through interviews and focus groups with 45 patients from diverse backgrounds, researchers identified 6 core psychosocial factors: interactions with healthcare systems, patient education, employment challenges, social and family support, socioeconomic status, and personal life experiences. Barriers to effective RA management included stressful life events, financial hardship, insufficient support networks, and mental health struggles. On the other hand, holistic care, supportive work environments, financial stability, and strong social connections emerged as protective influences. ³¹

The study underscored the complex interplay of biological, psychological, and social factors in managing RA, advocating for a comprehensive biopsychosocial approach. Participants highlighted the need for improved RA education, particularly around mental health, lifestyle changes, and non-pharmacological strategies. Recommendations included the development of culturally relevant educational materials and better integration of medical, social, and psychological services. Patient-led initiatives, family-based interventions, and adaptable healthcare models were proposed as strategies to address the diverse and interconnected needs of RA patients, promoting more equitable and holistic care. ³¹

Disease-Specific Insights and Lifestyle Interventions

Systemic Lupus Erythematosus (SLE)

• • Diet: Avoidance of ultra-processed foods and adherence to anti-inflammatory diets may mitigate disease activity.

• • Stress: A study demonstrated that 74% of lupus patients reported worsening symptoms after daily stress events. ²³

Rheumatoid Arthritis (RA)

• • Cardiovascular Risk: RA patients are nearly twice as likely to develop heart disease. The Mediterranean diet and addressing metabolic syndrome components (obesity, dyslipidemia, hypertension) are critical.^12,32

• • Nutritional Studies: Intake of omega-3 fatty acids, vitamin E, and selenium reduces inflammation, while excess omega-6 fatty acids exacerbate it. ³³

Sjögren’s Syndrome

• • Sleep and Depression: Addressing underlying depression and poor sleep hygiene is essential for managing fatigue and improving quality of life. ²¹

• • Exercise: Tailored physical activity prescriptions should account for multisystem involvement and fatigue levels.

Myositis

• • Exercise: Contrary to outdated beliefs, exercise benefits inflammatory myopathies by inducing anti-inflammatory molecular changes. ¹⁴

• • Diet: Foods mimicking statins, such as red yeast rice, soy, and oyster mushrooms, should be reviewed as they could worsen patients with myositis including necrotizing myopathy. ³⁴

Addressing Research Gaps

Despite promising findings, research in lifestyle medicine for CTDs faces limitations:

• • Dietary studies often rely on self-reported data, introducing bias. For example, patients may inaccurately report food intake, leading to inconsistent data.

• • Short study durations make it challenging to assess long-term effects. Longitudinal studies examining sustained dietary patterns, such as adherence to anti-inflammatory diets like the Mediterranean or DASH diets, are needed to evaluate their cumulative impact on disease progression.

• • Variability in outcome measures complicates comparisons across studies. Standardized biomarkers of inflammation, such as CRP, IL-6, and TNF-α levels, along with consistent clinical endpoints, could help address this issue and provide more reliable results.

• • Long-term, controlled trials are needed to confirm the causative role of lifestyle interventions in disease modification and minimize risk of confounding.

Conclusion

Lifestyle medicine offers an effective, patient-centered approach to managing CTDs. By integrating nutrition, physical activity, stress management, and other lifestyle adjustments into traditional treatment plans, healthcare providers can empower patients to improve their quality of life and potentially reduce reliance on medications. Multidisciplinary care, including nutritionists, physical therapists, and mental health professionals, is essential for optimizing outcomes in these complex diseases.

ORCID iD

Neha Bhanusali https://orcid.org/0000-0003-1800-3747